Alto Neuroscience (NYSE:ANRO) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Alto Neuroscience (NYSE:ANRO) from a sell rating to a strong sell rating in a report issued on Saturday morning.

Several other analysts have also commented on ANRO. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Wedbush upped their price target on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Zacks Research cut Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Bank of America started coverage on Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Chardan Capital restated a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Stock Up 0.8%

Shares of ANRO opened at $27.30 on Friday. Alto Neuroscience has a 52-week low of $3.00 and a 52-week high of $28.85. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The stock has a fifty day simple moving average of $24.23 and a two-hundred day simple moving average of $22.01. The company has a market capitalization of $957.78 million, a PE ratio of -11.28 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities analysts forecast that Alto Neuroscience will post -3.14 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently bought and sold shares of the company. Commodore Capital LP grew its position in Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after acquiring an additional 900,000 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after purchasing an additional 1,535,000 shares in the last quarter. Perceptive Advisors LLC lifted its position in shares of Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after purchasing an additional 12,000 shares during the period. Finally, Spruce Street Capital LP boosted its stake in shares of Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.